• Johnson & Johnson Innovation-JJDC will make an equity investment in Triastek under a strategic oral medicines collaboration.
• The deal pairs Johnson & Johnson drug development capabilities with Triastek’s 3D printing technology for oral delivery of peptides.
• The companies entered a Collaboration and License Agreement through Janssen Pharmaceutica NV on Oct. 9, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson Innovation-JJDC Inc. published the original content used to generate this news brief on October 14, 2026, and is solely responsible for the information contained therein.